immatics is a clinical-stage biopharmaceutical company dedicated to developing advanced immunotherapies that are active against cancer.
Our goal is to spearhead a new era in the treatment of cancer by enabling patients to live significantly longer and better lives than with today’s therapies.
We aim to achieve this by using multiple and relevant peptides that specifically activate T cells, specialized white blood cells, of the patient’s immune system against cancer cells. Our technology can also lead towards the development novel immunotherapies based on antibodies and T-cell receptors.
Our lead product, IMA901 for the treatment of kidney cancer, is in a global phase 3 clinical trial. Our other clinical-stage products are IMA910 for the treatment of colorectal cancer, which has completed a multi-center phase 2 clinical trial, and IMA950 for the treatment of brain cancer, which is in phase 1 clinical studies with partners. We also have active earlier programs in several other tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer being developed in collaboration with our partner Roche.
- -- 25 November 2013
EU-funded HepaVAC project to develop a vaccine for liver cancer has kicked off
- The HepaVAC project aims to develop therapeutic vaccination strategies for treatment of hepatocellular carcinoma (HCC) ... read more
- -- 13 November 2013
immatics and Roche sign cancer vaccine and immunotherapy collaboration
- Collaboration spans the discovery, development and commercialization of cancer vaccines and other cancer immunotherapies in ... read more
- -- 29 October 2013
Paper on actively personalized immunotherapies published in Nature Biotechnology
- The international science journal Nature Biotechnology published a peer-reviewed correspondence by the Regulatory ... read more
Renal cell cancer phase 3 clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: France, Germany, Hungary, Italy, Poland, Russia, UK, USA, Netherlands, Norway
Glioblastoma phase 1 clinical trials
Drug: Peptide-based glioma vaccine IMA950...read more
Participating countries: UK & USA
Selected immatics publications
immatics fact sheet